# Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI)

> **NCT01226615** · PHASE4 · UNKNOWN · sponsor: **Bioiberica** · enrollment: 64 (actual)

## Conditions studied

- Knee Osteoarthritis

## Interventions

- **DRUG:** Chondroitin sulphate (Condrosan®)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01226615
- **Lead sponsor:** Bioiberica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-10
- **Primary completion:** 2011-10
- **Final completion:** 2012-12
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2012-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01226615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01226615, "Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01226615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*